Joseph Lim, MD
Research & Publications
Biography
News
Research Summary
Dr. Lim's primary clinical and research interests are focused on acute and chronic liver diseases, with emphasis on: 1) Chronic hepatitis B and C infections; 2) Fatty liver disorders, including non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH); and 3) Complications of cirrhosis and portal hypertension.
Extensive Research Description
I would be pleased to work with trainees and scientists who are interested in studying health outcomes in patients with chronic liver disease, with particular attention to chronic hepatitis B and C infections, fatty liver disease, liver cirrhosis and complications of portal hypertension, and hepatocellular carcinoma. I am an investigator in several national or international multicenter cohort studies evaluating health outcomes focused on hepatitis B and hepatitis C therapy, and a VA cohort study evaluating liver disease outcomes in patients with or without HIV coinfection.
Coauthors
Research Interests
Delivery of Health Care; Hepatitis D; Fatty Liver; Health Services Research; Hepatitis B; Hepatitis C; Carcinoma, Hepatocellular; Liver Cirrhosis; Liver Neoplasms; Quality of Health Care; Clinical Trial
Public Health Interests
Hepatitis
Selected Publications
- AGA Clinical Practice Update on Diagnosis and Management of Acute Hepatic Porphyrias: Expert ReviewWang B, Bonkovsky H, Lim J, Balwani M. AGA Clinical Practice Update on Diagnosis and Management of Acute Hepatic Porphyrias: Expert Review Gastroenterology 2023, 164: 484-491. PMID: 36642627, DOI: 10.1053/j.gastro.2022.11.034.
- Treating Hepatitis C in Individuals With Previous Incarceration: The Veterans Health Administration, 2012–2019Hawks L, Wang E, Butt A, Crystal S, Keith McInnes D, Re V, Cartwright E, Puglisi L, Haque L, Lim J, Justice A, McGinnis K. Treating Hepatitis C in Individuals With Previous Incarceration: The Veterans Health Administration, 2012–2019 American Journal Of Public Health 2022, 113: 162-165. PMID: 36480765, PMCID: PMC9850617, DOI: 10.2105/ajph.2022.307152.
- Association Between Alcohol Use Disorder and Receipt of Direct-Acting Antiviral Hepatitis C Virus TreatmentHaque L, Fiellin D, Tate J, Esserman D, Bhattacharya D, Butt A, Crystal S, Edelman E, Gordon A, Lim J, Tetrault J, Williams E, Bryant K, Cartwright E, Rentsch C, Justice A, Re V, McGinnis K. Association Between Alcohol Use Disorder and Receipt of Direct-Acting Antiviral Hepatitis C Virus Treatment JAMA Network Open 2022, 5: e2246604. PMID: 36515952, PMCID: PMC9856353, DOI: 10.1001/jamanetworkopen.2022.46604.
- ReplyLong M, Noureddin M, Lim J. Reply Gastroenterology 2022, 164: 503. PMID: 36379247, DOI: 10.1053/j.gastro.2022.10.037.
- AGA Clinical Practice Update: Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Lean Individuals: Expert ReviewLong MT, Noureddin M, Lim JK. AGA Clinical Practice Update: Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Lean Individuals: Expert Review Gastroenterology 2022, 163: 764-774.e1. PMID: 35842345, PMCID: PMC9398982, DOI: 10.1053/j.gastro.2022.06.023.
- Care of the Patient With Abnormal Liver Test Results.Tran AN, Lim JK. Care of the Patient With Abnormal Liver Test Results. Annals Of Internal Medicine 2021, 174: ITC129-ITC144. PMID: 34516271, DOI: 10.7326/AITC202109210.
- Abnormal Liver Tests in COVID‐19: A Retrospective Observational Cohort Study of 1,827 Patients in a Major U.S. Hospital NetworkHundt MA, Deng Y, Ciarleglio MM, Nathanson MH, Lim JK. Abnormal Liver Tests in COVID‐19: A Retrospective Observational Cohort Study of 1,827 Patients in a Major U.S. Hospital Network Hepatology 2020, 72: 1169-1176. PMID: 32725890, PMCID: PMC9258788, DOI: 10.1002/hep.31487.
- Clinical Outcome Event Adjudication in a 10-Year Prospective Study of Nucleos(t)ide Analogue Therapy for Chronic Hepatitis BLim JK, Chang AY, Zaman A, Martin P, Fernandez-Rodriguez CM, Korkmaz M, Rossi S, Ford JM, Noonan T, Cooney E, Navarro V, Colombato L. Clinical Outcome Event Adjudication in a 10-Year Prospective Study of Nucleos(t)ide Analogue Therapy for Chronic Hepatitis B Journal Of Clinical And Translational Hepatology 2020, 8: 377-384. PMID: 33447520, PMCID: PMC7782110, DOI: 10.14218/jcth.2020.00039.
- AGA Institute Rapid Review and Recommendations on the Role of Pre-Procedure SARS-CoV-2 Testing and EndoscopySultan S, Siddique SM, Altayar O, Caliendo AM, Davitkov P, Feuerstein JD, Francis D, Inadomi J, Lim JK, Falck-Ytter Y, Mustafa RA, Association A. AGA Institute Rapid Review and Recommendations on the Role of Pre-Procedure SARS-CoV-2 Testing and Endoscopy Gastroenterology 2020, 159: 1935-1948.e5. PMID: 32735862, PMCID: PMC7386603, DOI: 10.1053/j.gastro.2020.07.043.
- Prevalence of Chronic Hepatitis B Virus Infection in the United States.Lim JK, Nguyen MH, Kim WR, Gish R, Perumalswami P, Jacobson IM. Prevalence of Chronic Hepatitis B Virus Infection in the United States. The American Journal Of Gastroenterology 2020, 115: 1429-1438. PMID: 32483003, DOI: 10.14309/ajg.0000000000000651.
- AGA Institute Rapid Review of the Gastrointestinal and Liver Manifestations of COVID-19, Meta-Analysis of International Data, and Recommendations for the Consultative Management of Patients with COVID-19Sultan S, Altayar O, Siddique SM, Davitkov P, Feuerstein JD, Lim JK, Falck-Ytter Y, El-Serag HB, . AGA Institute Rapid Review of the Gastrointestinal and Liver Manifestations of COVID-19, Meta-Analysis of International Data, and Recommendations for the Consultative Management of Patients with COVID-19 Gastroenterology 2020, 159: 320-334.e27. PMID: 32407808, PMCID: PMC7212965, DOI: 10.1053/j.gastro.2020.05.001.
- AGA Rapid Recommendations for Gastrointestinal Procedures During the COVID-19 PandemicSultan S, Lim JK, Altayar O, Davitkov P, Feuerstein JD, Siddique SM, Falck-Ytter Y, El-Serag HB, Institute A. AGA Rapid Recommendations for Gastrointestinal Procedures During the COVID-19 Pandemic Gastroenterology 2020, 159: 739-758.e4. PMID: 32247018, PMCID: PMC7118600, DOI: 10.1053/j.gastro.2020.03.072.
- Healthcare resource utilization and costs by disease severity in an insured national sample of US patients with chronic hepatitis BNguyen MH, Ozbay AB, Liou I, Meyer N, Gordon SC, Dusheiko G, Lim JK. Healthcare resource utilization and costs by disease severity in an insured national sample of US patients with chronic hepatitis B Journal Of Hepatology 2018, 70: 24-32. PMID: 30287341, DOI: 10.1016/j.jhep.2018.09.021.
- An expert consensus for the management of chronic hepatitis B in Asian AmericansTong MJ, Pan CQ, Han S, Lu D, Raman S, Hu K, Lim JK, Hann HW, Min AD. An expert consensus for the management of chronic hepatitis B in Asian Americans Alimentary Pharmacology & Therapeutics 2018, 47: 1181-1200. PMID: 29479728, PMCID: PMC5900913, DOI: 10.1111/apt.14577.
- Safety and Effectiveness of Ledipasvir and Sofosbuvir, With or Without Ribavirin, in Treatment-Experienced Patients With Genotype 1 Hepatitis C Virus Infection and CirrhosisLim JK, Liapakis AM, Shiffman ML, Lok AS, Zeuzem S, Terrault NA, Park JS, Landis CS, Hassan M, Gallant J, Kuo A, Pockros PJ, Vainorius M, Akushevich L, Michael L, Fried MW, Nelson DR, Ben-Ari Z, Group H. Safety and Effectiveness of Ledipasvir and Sofosbuvir, With or Without Ribavirin, in Treatment-Experienced Patients With Genotype 1 Hepatitis C Virus Infection and Cirrhosis Clinical Gastroenterology And Hepatology 2018, 16: 1811-1819.e4. PMID: 29306043, PMCID: PMC6034985, DOI: 10.1016/j.cgh.2017.12.037.
- Practice Patterns in Hepatitis B Virus Screening Before Cancer Chemotherapy in a Major US Hospital NetworkKwak YE, Stein SM, Lim JK. Practice Patterns in Hepatitis B Virus Screening Before Cancer Chemotherapy in a Major US Hospital Network Digestive Diseases And Sciences 2017, 63: 61-71. PMID: 29177849, DOI: 10.1007/s10620-017-4850-1.
- Survival after treatment with curative intent for hepatocellular carcinoma among patients with vs without non‐alcoholic fatty liver diseaseWong CR, Njei B, Nguyen MH, Nguyen A, Lim JK. Survival after treatment with curative intent for hepatocellular carcinoma among patients with vs without non‐alcoholic fatty liver disease Alimentary Pharmacology & Therapeutics 2017, 46: 1061-1069. PMID: 28960360, DOI: 10.1111/apt.14342.
- American Gastroenterological Association Institute Guideline on the Role of Elastography in the Evaluation of Liver FibrosisLim JK, Flamm SL, Singh S, Falck-Ytter YT, Association C, Gerson L, Hirano I, Nguyen G, Rubenstein J, Smalley W, Stollman N, Sultan S, Vege S, Wani S, Weinberg D, Yang Y. American Gastroenterological Association Institute Guideline on the Role of Elastography in the Evaluation of Liver Fibrosis Gastroenterology 2017, 152: 1536-1543. PMID: 28442119, DOI: 10.1053/j.gastro.2017.03.017.
- Medicaid Reimbursement for Oral Direct Antiviral Agents for the Treatment of Chronic Hepatitis COoka K, Connolly JJ, Lim JK. Medicaid Reimbursement for Oral Direct Antiviral Agents for the Treatment of Chronic Hepatitis C The American Journal Of Gastroenterology 2017, 112: 828. PMID: 28374816, DOI: 10.1038/ajg.2017.87.
- ACG Clinical Guideline: Evaluation of Abnormal Liver ChemistriesKwo PY, Cohen SM, Lim JK. ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries The American Journal Of Gastroenterology 2016, 112: 18. PMID: 27995906, DOI: 10.1038/ajg.2016.517.
- Optimal timing for hepatitis C therapy in US patients eligible for liver transplantation: a cost‐effectiveness analysisNjei B, McCarty TR, Fortune BE, Lim JK. Optimal timing for hepatitis C therapy in US patients eligible for liver transplantation: a cost‐effectiveness analysis Alimentary Pharmacology & Therapeutics 2016, 44: 1090-1101. PMID: 27640785, DOI: 10.1111/apt.13798.
- Disparities in hepatitis C testing in U.S. veterans born 1945–1965Sarkar S, Esserman DA, Skanderson M, Levin FL, Justice AC, Lim JK. Disparities in hepatitis C testing in U.S. veterans born 1945–1965 Journal Of Hepatology 2016, 65: 259-265. PMID: 27130843, PMCID: PMC4955712, DOI: 10.1016/j.jhep.2016.04.012.
- Entecavir safety and effectiveness in a national cohort of treatment‐naïve chronic hepatitis B patients in the US – the ENUMERATE studyAhn J, Lee HM, Lim JK, Pan CQ, Nguyen MH, Kim W, Mannalithara A, Trinh H, Chu D, Tran T, Min A, Do S, Te H, Reddy KR, Lok AS. Entecavir safety and effectiveness in a national cohort of treatment‐naïve chronic hepatitis B patients in the US – the ENUMERATE study Alimentary Pharmacology & Therapeutics 2015, 43: 134-144. PMID: 26510638, PMCID: PMC4926997, DOI: 10.1111/apt.13440.
- Drug Authorization for Sofosbuvir/Ledipasvir (Harvoni) for Chronic HCV Infection in a Real-World Cohort: A New Barrier in the HCV Care CascadeDo A, Mittal Y, Liapakis A, Cohen E, Chau H, Bertuccio C, Sapir D, Wright J, Eggers C, Drozd K, Ciarleglio M, Deng Y, Lim JK. Drug Authorization for Sofosbuvir/Ledipasvir (Harvoni) for Chronic HCV Infection in a Real-World Cohort: A New Barrier in the HCV Care Cascade PLOS ONE 2015, 10: e0135645. PMID: 26312999, PMCID: PMC4552165, DOI: 10.1371/journal.pone.0135645.
- Emerging trends in hepatocellular carcinoma incidence and mortalityNjei B, Rotman Y, Ditah I, Lim JK. Emerging trends in hepatocellular carcinoma incidence and mortality Hepatology 2014, 61: 191-199. PMID: 25142309, PMCID: PMC4823645, DOI: 10.1002/hep.27388.
- American Gastroenterological Association Institute Guideline on the Prevention and Treatment of Hepatitis B Virus Reactivation During Immunosuppressive Drug TherapyReddy KR, Beavers KL, Hammond SP, Lim JK, Falck-Ytter YT. American Gastroenterological Association Institute Guideline on the Prevention and Treatment of Hepatitis B Virus Reactivation During Immunosuppressive Drug Therapy Gastroenterology 2014, 148: 215-219. PMID: 25447850, DOI: 10.1053/j.gastro.2014.10.039.
- Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised studyLawitz E, Sulkowski MS, Ghalib R, Rodriguez-Torres M, Younossi ZM, Corregidor A, DeJesus E, Pearlman B, Rabinovitz M, Gitlin N, Lim JK, Pockros PJ, Scott JD, Fevery B, Lambrecht T, Ouwerkerk-Mahadevan S, Callewaert K, Symonds WT, Picchio G, Lindsay KL, Beumont M, Jacobson IM. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study The Lancet 2014, 384: 1756-1765. PMID: 25078309, DOI: 10.1016/s0140-6736(14)61036-9.
- Relationship Between Alcohol Use Categories and Noninvasive Markers of Advanced Hepatic Fibrosis in HIV-Infected, Chronic Hepatitis C Virus–Infected, and Uninfected PatientsLim JK, Tate JP, Fultz SL, Goulet JL, Conigliaro J, Bryant KJ, Gordon AJ, Gibert C, Rimland D, Goetz MB, Klein MB, Fiellin DA, Justice AC, Re V. Relationship Between Alcohol Use Categories and Noninvasive Markers of Advanced Hepatic Fibrosis in HIV-Infected, Chronic Hepatitis C Virus–Infected, and Uninfected Patients Clinical Infectious Diseases 2014, 58: 1449-1458. PMID: 24569533, PMCID: PMC4001286, DOI: 10.1093/cid/ciu097.
- Management and Treatment of Patients With Cirrhosis and Portal Hypertension: Recommendations From the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C ProgramGarcia-Tsao G, Lim J. Management and Treatment of Patients With Cirrhosis and Portal Hypertension: Recommendations From the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program The American Journal Of Gastroenterology 2009, 104: 1802. PMID: 19455106, DOI: 10.1038/ajg.2009.191.
Clinical Trials
Conditions | Study Title |
---|---|
Diseases of the Digestive System - Liver | A Phase 3 Study Evaluating Long-term Efficacy and Safety of Lanifibranor in Adult Patients With (NASH) and Fibrosis 2 (F2)/Fibrosis 3 (F3) Stage of Liver Fibrosis (NATiV3) |
Diseases of the Digestive System - Liver | Metabolic Interventions to Resolve Non-alcoholic Steatohepatitis (NASH) With Fibrosis (MIRNA) (MIRNA) |
Diseases of the Digestive System - Liver | A Study to Assess the Efficacy and Safety of VK2809 for 52 Weeks in Subjects With Biopsy Proven NASH (VOYAGE) |
Hepatitis | An Observational Study of Patients Undergoing Therapy for Chronic Hepatitis B (HBV) Infection |